This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: July 10, 2008
Last updated: January 13, 2012
Last verified: January 2012
Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice

Cardiovascular Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: CARE - Quality Development in Cardiovascular Disease in General Practice

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol, HDL -cholesterol, LDL-Cholesterol, Blood pressure, Exercise, Waist-circumference, BMI, Smoking status, fasting plasma-glucose, medication taken [ Time Frame: As needed, min. baseline and after 6 months ]

Secondary Outcome Measures:
  • Number of visits pr. patients, drop-out [ Time Frame: Annually ]

Enrollment: 2193
Study Start Date: April 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Patients in secondary prevention of cardiovascular disease in primary care


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Patients in secondary prevention of cardiopathy (ischaemic heart disease, claudication intermittence, thrombotic apoplexy cerebri, diabetes) who are not followed in an outpatient department.

Exclusion Criteria:

  • Patients who suffer from diabetic nephropathy will be excluded
  • According to the general practitioners appraisal, patients who suffer from severe co morbidity can be excluded as well.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00713960

  Show 66 Study Locations
Sponsors and Collaborators
Study Chair: Henrik Ommen, MD Lægerne i Løgumkloster I/S, Denmark
Study Chair: Dorte Knudsen Lægerne Sønderåparken, Denmark
  More Information

Responsible Party: AstraZeneca Identifier: NCT00713960     History of Changes
Other Study ID Numbers: NIS-CDK-DUM-2008/1
Study First Received: July 10, 2008
Last Updated: January 13, 2012

Keywords provided by AstraZeneca:
Quality development project
primary care nurses
cardiovascular disease
secondary prevention

Additional relevant MeSH terms:
Cardiovascular Diseases processed this record on September 20, 2017